These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 9865328)

  • 1. Leflunomide effectively treats naturally occurring immune-mediated and inflammatory diseases of dogs that are unresponsive to conventional therapy.
    Gregory CR; Stewart A; Sturges B; DeManvelle T; Cannon A; Ortega T; Harb M; Morris RE
    Transplant Proc; 1998 Dec; 30(8):4143-8. PubMed ID: 9865328
    [No Abstract]   [Full Text] [Related]  

  • 2. A Retrospective Study on the Safety and Efficacy of Leflunomide in Dogs.
    Sato M; Veir JK; Legare M; Lappin MR
    J Vet Intern Med; 2017 Sep; 31(5):1502-1507. PubMed ID: 28833582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of leflunomide for treatment of refractory inflammatory colorectal polyps in 15 Miniature Dachshunds.
    Fukushima K; Eguchi N; Ohno K; Kanemoto H; Takahashi M; Igarashi H; Ohmi A; Nakashima K; Tsujimoto H
    J Vet Med Sci; 2016 Feb; 78(2):265-9. PubMed ID: 26460312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulatory drugs and their application to the management of canine immune-mediated disease.
    Whitley NT; Day MJ
    J Small Anim Pract; 2011 Feb; 52(2):70-85. PubMed ID: 21265846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunosuppressive therapy in dogs and cats. Properties of drugs and their use in various immune-mediated diseases].
    Rieder J; Mischke R
    Tierarztl Prax Ausg K Kleintiere Heimtiere; 2018 Apr; 46(2):105-118. PubMed ID: 29727898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single- and multiple-dose pharmacokinetics and pharmacodynamics of leflunomide's active metabolite A77 1726 in normal Lewis rats.
    Silva HT; Shorthouse R; Morris RE
    Transplant Proc; 1996 Dec; 28(6):3092-4. PubMed ID: 8962197
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevention of experimental autoimmune diabetes in mice by treatment with leflunomide.
    Stosic-Grujicic S; Dimitrijevic M; Bartlett RR
    Transplant Proc; 1998 Dec; 30(8):4132-3. PubMed ID: 9865323
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetics of leflunomide in Chinese healthy volunteers.
    Li J; Yao HW; Jin Y; Zhang YF; Li CY; Li YH; Xu SY
    Acta Pharmacol Sin; 2002 Jun; 23(6):551-5. PubMed ID: 12060531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression.
    Chong AS; Huang W; Liu W; Luo J; Shen J; Xu W; Ma L; Blinder L; Xiao F; Xu X; Clardy C; Foster P; Williams JA
    Transplantation; 1999 Jul; 68(1):100-9. PubMed ID: 10428276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucocorticosteroids as immunosuppressive agents.
    Cohn LA
    Semin Vet Med Surg Small Anim; 1997 Aug; 12(3):150-6. PubMed ID: 9283238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of renal allograft polyoma BK virus infection with leflunomide.
    Josephson MA; Gillen D; Javaid B; Kadambi P; Meehan S; Foster P; Harland R; Thistlethwaite RJ; Garfinkel M; Atwood W; Jordan J; Sadhu M; Millis MJ; Williams J
    Transplantation; 2006 Mar; 81(5):704-10. PubMed ID: 16534472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azathioprine for treatment of immune-mediated diseases of dogs and cats.
    Beale KM
    J Am Vet Med Assoc; 1988 May; 192(9):1316-8. PubMed ID: 3391859
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of leflunomide for treatment of immune-mediated polyarthritis in dogs: 14 cases (2006-2008).
    Colopy SA; Baker TA; Muir P
    J Am Vet Med Assoc; 2010 Feb; 236(3):312-8. PubMed ID: 20113244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Not Available].
    Mucha D
    Tierarztl Prax Ausg K Kleintiere Heimtiere; 2018 Feb; 46(1):57-58. PubMed ID: 29571179
    [No Abstract]   [Full Text] [Related]  

  • 15. Mycophenolate mofetil and leflunomide: promising compounds for the treatment of skin diseases.
    Frieling U; Luger TA
    Clin Exp Dermatol; 2002 Oct; 27(7):562-70. PubMed ID: 12464151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of rheumatic diseases: current status and future prospective. Topics: II. Immunosuppressant/antirheumatic drugs; 5. Leflunomide and mizoribine].
    Sawada T
    Nihon Naika Gakkai Zasshi; 2011 Oct; 100(10):2929-35. PubMed ID: 22175133
    [No Abstract]   [Full Text] [Related]  

  • 17. [Leflunomide--a new drug for pharmacological immunomodulation].
    Wozel G; Pfeiffer C
    Hautarzt; 2002 May; 53(5):309-15. PubMed ID: 12063741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potentiation of immunosuppressive efficacy by combining the novel leflunomide analog, HMR 279, with microemulsion cyclosporine in a rat lung transplant model.
    Hausen B; Boeke K; Berry GJ; Gummert JF; Christians U; Morris RE
    Transplantation; 1999 Feb; 67(3):354-9. PubMed ID: 10030278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study.
    van Woerkom JM; Kruize AA; Geenen R; van Roon EN; Goldschmeding R; Verstappen SM; van Roon JA; Bijlsma JW
    Ann Rheum Dis; 2007 Aug; 66(8):1026-32. PubMed ID: 17223657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leflunomide: friend or foe for systemic lupus erythematosus?
    Wu GC; Xu XD; Huang Q; Wu H
    Rheumatol Int; 2013 Feb; 33(2):273-6. PubMed ID: 22961090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.